Comprehensive Stock Comparison
Compare The Oncology Institute, Inc. (TOI) vs DaVita Inc. (DVA) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth |  TOI | 21.3% revenue growth vs DVA's 6.5% |
| Quality / Margins |  DVA | 5.5% net margin vs TOI's -14.4% |
| Stability / Safety | DVA | Beta 0.35 vs TOI's 1.56, lower leverage |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | TOI | +307.7% vs DVA's +6.5% |
| Efficiency (ROA) | DVA | 4.3% ROA vs TOI's -40.5%, ROIC 10.5% vs -40.9% |
Who Each Stock Is For
Income & stability
DVADividend streak 3 yrs, beta 0.35
Growth exposure
TOIRev growth 21.3%, EPS growth 22.8%, 3Y rev CAGR 24.7%
Long-term compounding (10Y)
DVA113.8% 10Y total return vs TOI's -71.0%
Sleep-well-at-night portfolio
DVALower volatility, beta 0.35, current ratio 1.29x
Defensive / Recession hedge
DVABeta 0.35, current ratio 1.29x
Business Model
What each company does and how it makes money
The Oncology Institute operates a network of outpatient cancer care clinics providing comprehensive oncology services including chemotherapy, radiation, and clinical trial management. It generates revenue primarily from fee-for-service medical oncology treatments — with infusion services and physician consultations being major contributors — supplemented by clinical trial management fees. The company's competitive advantage lies in its integrated care model that combines clinical services with research capabilities across its 67 clinic locations, creating a scalable platform for community-based cancer care.
DaVita is a leading provider of kidney dialysis services for patients with chronic kidney failure. It generates revenue primarily from operating outpatient dialysis centers — which provide the bulk of its income — along with related lab services, home-based dialysis, and integrated care arrangements. The company's scale and network of over 2,800 U.S. centers create significant barriers to entry and operational efficiencies in a capital-intensive, regulated healthcare segment.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
DVA 3TOI 1DVA4/6 metricsTOI2/3 metricsDVA7/9 metricsDVA2/2 metricsDVA leads in 3 of 6 categories (Financial Metrics, Profitability & Efficiency). TOI leads in 1 (Valuation Metrics). 1 tied.
Financial Metrics (TTM)
DVA is the larger business by revenue, generating $13.6B annually — 29.6x TOI's $461M. DVA is the more profitable business, keeping 5.5% of every revenue dollar as net income compared to TOI's -14.4%. On growth, TOI holds the edge at +36.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | TOIThe Oncology Inst… | DVADaVita Inc. |
|---|---|---|
| RevenueTrailing 12 months | $461M | $13.6B |
| EBITDAEarnings before interest/tax | -$34M | $2.7B |
| Net IncomeAfter-tax profit | -$66M | $747M |
| Free Cash FlowCash after capex | -$28M | $1.3B |
| Gross MarginGross profit ÷ Revenue | +14.8% | +30.9% |
| Operating MarginEBIT ÷ Revenue | -8.9% | +14.9% |
| Net MarginNet income ÷ Revenue | -14.4% | +5.5% |
| FCF MarginFCF ÷ Revenue | -6.0% | +9.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | +36.7% | +9.9% |
| EPS Growth (YoY)Latest quarter vs prior year | +22.2% | -20.7% |
Valuation Metrics
| Metric | TOIThe Oncology Inst… | DVADaVita Inc. |
|---|---|---|
| Market CapShares × price | $213M | $10.1B |
| Enterprise ValueMkt cap + debt − cash | $287M | $24.4B |
| Trailing P/EPrice ÷ TTM EPS | -3.96x | 16.62x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 10.63x |
| PEG RatioP/E ÷ EPS growth rate | — | 2.29x |
| EV / EBITDAEnterprise value multiple | — | 8.94x |
| Price / SalesMarket cap ÷ Revenue | 0.54x | 0.74x |
| Price / BookPrice ÷ Book value/share | 58.84x | 11.46x |
| Price / FCFMarket cap ÷ FCF | — | 7.69x |
Profitability & Efficiency
DVA delivers a 64.5% return on equity — every $100 of shareholder capital generates $64 in annual profit, vs $-2 for TOI. DVA carries lower financial leverage with a 12.99x debt-to-equity ratio, signaling a more conservative balance sheet compared to TOI's 34.31x. On the Piotroski fundamental quality scale (0–9), DVA scores 5/9 vs TOI's 3/9, reflecting solid financial health.
| Metric | TOIThe Oncology Inst… | DVADaVita Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -2.1% | +64.5% |
| ROA (TTM)Return on assets | -40.5% | +4.3% |
| ROICReturn on invested capital | -40.9% | +10.5% |
| ROCEReturn on capital employed | -40.8% | +14.0% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 5 |
| Debt / EquityFinancial leverage | 34.31x | 12.99x |
| Net DebtTotal debt minus cash | $73M | $14.3B |
| Cash & Equiv.Liquid assets | $50M | $758M |
| Total DebtShort + long-term debt | $123M | $15.0B |
| Interest CoverageEBIT ÷ Interest expense | -4.92x | 3.51x |
Total Returns (with DRIP)
A $10,000 investment in DVA five years ago would be worth $14,520 today (with dividends reinvested), compared to $2,772 for TOI. Over the past 12 months, TOI leads with a +307.7% total return vs DVA's +6.5%. The 3-year compound annual growth rate (CAGR) favors TOI at 26.2% vs DVA's 23.4% — a key indicator of consistent wealth creation.
| Metric | TOIThe Oncology Inst… | DVADaVita Inc. |
|---|---|---|
| YTD ReturnYear-to-date | -23.3% | +31.6% |
| 1-Year ReturnPast 12 months | +307.7% | +6.5% |
| 3-Year ReturnCumulative with dividends | +101.0% | +88.0% |
| 5-Year ReturnCumulative with dividends | -72.3% | +45.2% |
| 10-Year ReturnCumulative with dividends | -71.0% | +113.8% |
| CAGR (3Y)Annualised 3-year return | +26.2% | +23.4% |
Risk & Volatility
DVA is the less volatile stock with a 0.35 beta — it tends to amplify market swings less than TOI's 1.56 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. DVA currently trades 95.5% from its 52-week high vs TOI's 57.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | TOIThe Oncology Inst… | DVADaVita Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.56x | 0.35x |
| 52-Week HighHighest price in past year | $4.88 | $157.91 |
| 52-Week LowLowest price in past year | $0.60 | $101.00 |
| % of 52W HighCurrent price vs 52-week peak | +57.7% | +95.5% |
| RSI (14)Momentum oscillator 0–100 | 52.0 | 73.8 |
| Avg Volume (50D)Average daily shares traded | 1.5M | 959K |
Analyst Outlook
Wall Street rates TOI as "Buy" and DVA as "Hold". Consensus price targets imply 77.7% upside for TOI (target: $5) vs 11.9% for DVA (target: $169).
| Metric | TOIThe Oncology Inst… | DVADaVita Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold |
| Price TargetConsensus 12-month target | $5.00 | $168.67 |
| # AnalystsCovering analysts | 3 | 23 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 3 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +17.8% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Jun 20 | Mar 26 | Change |
|---|---|---|---|
| The Oncology Instit… (TOI) | 100 | 29.01 | -71.0% |
| DaVita Inc. (DVA) | 100 | 186.94 | +86.9% |
DaVita Inc. (DVA) returned +45% over 5 years vs The Oncology Instit… (TOI)'s -72%. A $10,000 investment in DVA 5 years ago would be worth $14,520 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| The Oncology Instit… (TOI) | $155M | $393M | +153.2% |
| DaVita Inc. (DVA) | $14.7B | $13.6B | -7.5% |
DaVita Inc.'s revenue grew from $14.7B (2016) to $13.6B (2025) — a -0.9% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| The Oncology Instit… (TOI) | -2.6% | -16.4% | -535.2% |
| DaVita Inc. (DVA) | 6.0% | 5.5% | -8.3% |
DaVita Inc.'s net margin went from 6% (2016) to 5% (2025).
Chart 4P/E Ratio History — 9 Years
| Stock | 2017 | 2025 | Change |
|---|---|---|---|
| DaVita Inc. (DVA) | 20.8 | 12.5 | -39.9% |
DaVita Inc. has traded in a 11x–21x P/E range over 9 years; current trailing P/E is ~17x.
Chart 5EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| The Oncology Instit… (TOI) | -0.06 | -0.71 | -1037.8% |
| DaVita Inc. (DVA) | 4.29 | 9.07 | +111.4% |
DaVita Inc.'s EPS grew from $4.29 (2016) to $9.07 (2025) — a 9% CAGR.
Chart 6Free Cash Flow — 5 Years
The Oncology Institute, Inc. generated $-30M FCF in 2024 (+15% vs 2021). DaVita Inc. generated $1B FCF in 2025 (+2% vs 2021).
TOI vs DVA: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is TOI or DVA a better buy right now?
DaVita Inc. (DVA) offers the better valuation at 16.6x trailing P/E (10.6x forward), making it the more compelling value choice. Analysts rate The Oncology Institute, Inc. (TOI) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — TOI or DVA?
Over the past 5 years, DaVita Inc. (DVA) delivered a total return of +45.2%, compared to -72.3% for The Oncology Institute, Inc. (TOI). A $10,000 investment in DVA five years ago would be worth approximately $15K today (assuming dividends reinvested). Over 10 years, the gap is even starker: DVA returned +113.8% versus TOI's -71.0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — TOI or DVA?
By beta (market sensitivity over 5 years), DaVita Inc. (DVA) is the lower-risk stock at 0.35β versus The Oncology Institute, Inc.'s 1.56β — meaning TOI is approximately 351% more volatile than DVA relative to the S&P 500. On balance sheet safety, DaVita Inc. (DVA) carries a lower debt/equity ratio of 13% versus 34% for The Oncology Institute, Inc. — giving it more financial flexibility in a downturn.
04Which has better profit margins — TOI or DVA?
DaVita Inc. (DVA) is the more profitable company, earning 5.5% net margin versus -16.4% for The Oncology Institute, Inc. — meaning it keeps 5.5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DVA leads at 14.7% versus -15.3% for TOI. At the gross margin level — before operating expenses — DVA leads at 27.0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Is TOI or DVA more undervalued right now?
Analyst consensus price targets imply the most upside for TOI: 77.7% to $5.00.
06Which pays a better dividend — TOI or DVA?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is TOI or DVA better for a retirement portfolio?
For long-horizon retirement investors, DaVita Inc. (DVA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.35), +113.8% 10Y return). The Oncology Institute, Inc. (TOI) carries a higher beta of 1.56 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (DVA: +113.8%, TOI: -71.0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between TOI and DVA?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. In terms of investment character: TOI is a small-cap quality compounder stock; DVA is a mid-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.